ArticleFrontiers in oncology2023

Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt's lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib.

Yurim Jeong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.